

**Title:**

**Advanced esophageal neuroendocrine carcinoma**

**Authors:**

Fernando Muñoz Agel, Modesto-J. Varas Lorenzo

DOI: 10.17235/reed.2024.10437/2024

Link: [PubMed \(Epub ahead of print\)](#)

Please cite this article as:

Muñoz Agel Fernando, Varas Lorenzo Modesto-J.. Advanced esophageal neuroendocrine carcinoma. Rev Esp Enferm Dig 2024. doi: 10.17235/reed.2024.10437/2024.

*This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.*

## Advanced esophageal neuroendocrine carcinoma

Fernando Muñoz Agel and Modesto-J Varas Lorenzo

Gastrointestinal Ecoendoscopic Ultrasound Unit. Department of Gastroenterology and Hepatology. Centro Médico Teknon. Barcelona. Spain

Correspondence: Modesto-J Varas Lorenzo. Unidad de Ecoendoscopia. Centro Médico Teknon. c/ Marquesa Vilallonga 12. 08017 Barcelona, Spain

E-mail: modestoj.varas.ext@quironsalud.es

Keywords: Neuroendocrine carcinoma of the esophagus.

Author contributions: Data curation: F.M.A.; Writing – review & editing: M.V.L.

Conflicts of interest: the authors declare no conflicts of interest.

Dear Editor,

Neuroendocrine tumors of the esophagus represent 0.04-0.1 to 1.0 % of all neuroendocrine tumors (NETs) (1-3), and mainly affect males in their sixties, involve the middle and lower esophageal thirds, and manifest primarily with dysphagia. At diagnosis they are usually advanced, highly aggressive small-cell (90 %) or large-cell (10 %) neuroendocrine carcinomas (NECs) (2,3).

Case report:

A 65-year-old patient with progressive dysphagia and toxic syndrome underwent upper GI endoscopy, which revealed a stenosing lesion in the middle and lower thirds of the esophagus that the endoscope could pass. Biopsy showed a high-grade NET with Ki67 at 70%. The lesion was staged as G3 NEC. The study was completed with abdominal ultrasound and CT, their images showing multiple liver metastases that grew rapidly. No carcinoid syndrome (CS) was observed.

He was managed with chemotherapy and died from liver failure within 1 year after diagnosis.

Discussion

Recently, four NEC cases (3-5) were reported in your Journal, which are summarized and compared in Table 1.

As may be seen in this succinct review, esophageal NEC involved males over 60 years of age who had predominantly dysphagia. Most cases received chemotherapy because of advanced disease.

Treatment has not been standardized; for a lesion smaller than 1 cm, unusual, occasionally associated with Barrett's esophagus (3), endoscopic resection will be curative; however, all other lesions require recourse to neoadjuvant chemotherapy and surgery in order to prolong life expectancy. Only one case is reported in the literature as being disease-free after 5 years.

#### References:

1. Varas Lorenzo MJ, Muñoz Agel F, Abad Belando R, Sanchez-Vizcaino E. Prevalence of neuroendocrine tumors in gastrointestinal and hepatobiliary system. *Ann Colorectal Res* 2019; 7(2): e88004.
2. Taori K, Kirnake V, Junare PR, Padwale V. An Uncommon encounter: A comprehensive case report of an advanced esophageal neuroendocrine carcinoma. *Cureus* 2024; 16 (1): e53027. Doi: 107759/cureus.53027.
3. García Redondo M, Ruiz Pardo J, Sánchez Fuentes P, et al. Carcinoma neuroendocrino de células grandes en la unión esofagogástrica. Una entidad extremadamente infrecuente. *Rev Esp Enferm Dig* 2023; 115: 719-720.
4. Ortigao R, Isidoro R, Dinis-Ribeiro M, et al. A rare case of an esophageal neuroendocrine carcinoma arising on an endoscopic resection scar. *Rev Esp Enferm Dig* 2023; 115: 721-722.
5. Lopez Garcia M<sup>a</sup>L, Bravo Rodriguez M<sup>a</sup>T, Castro Zavaleta A, Calderón García AJ. Disfagia secundaria aun carcinoma neuroendocrino: un tumor esofágico infrecuente. *Rev Esp Enferm Dig* 2024; 116: 35-36.

Table 1.

NEC	Age	Sex	Presentation	Lesion	Site	NEC	Ki67	Imaging	Therapy	Survival
(2)	65	Male	Dysphagia	Ulcerated	Lower third	Small-cell	53 %	CT	Chemotherapy	Death
Case	65	Male	Dysphagia	Stenosing	Mid-Lower	Small-cell	70 %	CT/US	Chemotherapy	Death
(3)	65	Male	Pain	Ulcerated	Cardia	Large-cell	70 %	EUS/CT	Surgery	6 months
(4)	61	Female	Dysphagia	Ulcerated	Mid third	Small-cell	80 %	CT	?	?
(5)	68	Male	Dysphagia	Polypoid	Mid third	Large-cell	90 %	EUS/CT	Chemo + Surgery	
(5)	55	Female	Dysphagia	Stenosing	Mid third	Small-cell	95 %	CT	Palliative	Death

